Home >> About

News & Events

The Moulder Center for Drug Discovery Research has been awarded a 5 year NIH R01 grant to support the identification of novel therapies for the treatment of cocaine addiction and withdrawal.  Cocaine addiction is a chronic disease characterized by an inability to regulate drug-seeking behavior. The lifetime prevalence of cocaine addiction in the United States is 15.4% and there currently are no FDA-approved treatments for cocaine addiction.  The program will focus on developing compounds capable of increasing the expression of Glutamate Transporter 1 (GLT-1), an important component of glutamate re-uptake in the central nervous system.  Colleagues at John Hopkins University and the University of Florida will be collaborating with Moulder Center scientists on this $1.98 million project over the next 5 years.

The Moulder Center also added a powerful new research tool thanks to the efforts of Dr. Marlene Jacobson, who led a successful effort to obtain a National Institutes of Health Shared Instrument grant in June 2104 (NIH Project #1S10OD018195-01).  This $267K grant supported the acquisition of a Hamamatsu Functional Drug Discovery Screening System (FDSS) μCell instrument, a kinetic plate reader with an integrated dispensing head and imaging-based detector.  The FDSS μCell instrument provides the Moulder Center for Drug Discovery Research and the Temple University research community a high throughput screening platform to measure activities on G-protein coupled receptors and ion channels.  The addition of this system compliments the Moulder Centers existing infrastructure and represents a continuation of the Moulder Center’s commitment to explore cutting edge research and technology.

Martinsried/Munich, Germany, and Philadelphia, USA, April 29, 2014: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and The Moulder Center for Drug Discovery Research, a unit of Temple University’s School of Pharmacy, Philadelphia, Pa., USA, today announced a strategic alliance focused on the discovery of new therapeutic antibodies. Under the terms of the agreement, the Moulder Center will receive access to MorphoSys’s Ylanthia® technology for use in validating new disease-related targets and generating therapeutic antibody candidates. MorphoSys will receive an exclusive option to develop any resulting antibodies. Financial details of the agreement were not disclosed.

PHILADELPHIA--(BUSINESS WIRE)--Four promising technologies are one step closer to the marketplace thanks to funding from the University City Science Center’s QED Proof-of-Concept Program. Life science and health IT researchers from Drexel University, Temple University and Rutgers, The State University of New Jersey, received a total of $600,000 through the QED program to develop a potential drug therapy for Lou Gehrig’s disease; validate a new therapeutic compound for pancreatic cancer; develop software to analyze EEG readings and guide diagnosis; and improve communications skills of health care professionals.

We are pleased to announce internal grant awards for four drug discovery research projects to be conducted by groups of Temple faculty members. These awards are part of the Temple University Drug Discovery Initiative established in 2010 to encourage and support collaborative research with the Moulder Center for Drug Discovery Research in the School of Pharmacy.

Dr. Magid Abou-Gharbia has been appointed a Laura H. Carnell Professor, Temple University’s highest professorial honorific, effective July 1, 2013.

During the recent Temple Duquesne basketball game, Dr. Magid Abou-Gharbia, Professor of Medicinal Chemistry & Associate Dean for Research and Director of the Moulder Center and Dr. Nicole Sifontis, Clinical Associate Professor of Pharmacy Practice, were recognized by the Department of Athletics, for their extraordinary contributions to teaching, service and scholarship.

Started five years ago with the support of alumnus Lonnie Moulder and his wife, Sharon, the Moulder Center for Drug Discovery Research in the School of Pharmacy has grown to become the Greater Philadelphia region’s only fully integrated academic drug discovery center.

Dotmatics Limited, a leading provider of informatics solutions to the pharmaceutical and biotechnology industries, today announced that The Moulder Centre for Drug Discovery Research at Temple University have licensed Dotmatics’ suite of solutions to boost their drug discovery research efforts.

An innovative funding model designed to promote interdepartmental collaboration with the Moulder Center for Drug Discovery Research in Temple’s School of Pharmacy is already showing results.

Pages

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140